CYKLX
GrowthNDAOPHTHALMICSOLUTION/DROPS
Approved
Aug 2025
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYKLX is an ophthalmic solution approved by the FDA in August 2025 for delivery via eye drops. The mechanism of action, specific indications, and generic name remain undisclosed in available data, limiting clinical context. The product is positioned in the growth phase with a 12.4-year patent runway.
Growth12.4 years to LOE
Early-stage growth product with minimal competitive pressure offers significant opportunity for team expansion and market-building roles within Genomics.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CYKLX positions careers within Genomics across science, product engineering, and business development with 11 active linked roles. Growth-stage ophthalmic approvals typically attract strong technical and commercial talent, offering clear advancement paths within sponsor's genomics-focused infrastructure.
ScientistProduct Engineer
Worked on CYKLX at Genomics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.